About this trial
The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer \[11C\]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. This imaging method allows for the quantification of synaptic density in the living human brain and has the unprecedented ability to directly examine the synaptic pathology underlying neuropsychiatric disease. The neural synaptic pruning hypothesis posits that a key pathogenic process of schizophrenia is the over-exuberant elimination of neural synapses during development. The confirmation of reduced synaptic density in schizophrenia as evidenced by \[11C\]UCB-J has the potential to lead to a number of ground-breaking clinical innovations, such as laboratory-based diagnostics and prognostics, and novel, disease-modifying treatments.
Eligibility criteria
Qualifiers
18 - 65 years in age
On a stable medication regimen for at least two weeks prior to testing
A clinical diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder
Able to complete a PET-MR scan without the use of sedation
Disqualifiers
Active substance use within three months of testing
IQ < 70
Major medical neurological illness or significant head trauma
Pregnancy or breastfeeding
Trial design
Treatments tested in this trial
- [11C]UCB-J radiotracer
- PET-MR
Treatment groups
Sponsors and collaborators
Davidzon, Guido, M.D.
Lead sponsor
Stanford University
Sponsor institution
Weston Havens Foundation
Collaborator